Cutaneous Radiation-Associated Angiosarcoma of the Breast following Modern Hypofractionated 3DCRT: A Case Report with Radiation Technique Analysis and Implications for Ongoing Surveillance
Case Reports in Oncology · 2026-08-31 · 19 (1) · 1650-1662
DOI: 10.1159/cro/abzag039 ↗Abstract
Introduction: Radiation-associated angiosarcoma of the breast (RAASB) is a rare but aggressive late complication of breast-conserving therapy, with an incidence that has increased alongside the growing adoption of breast-conserving surgery and adjuvant radiotherapy. Despite advances in modern conformal radiation techniques, RAASB continues to occur in the contemporary era. The true incidence under modern hypofractionated three-dimensional conformal radiotherapy (3DCRT) regimens has not been established in prospective comparative studies, and clinicians must maintain vigilance for this complication regardless of the radiation technique employed. Case Presentation: We report a case of RAASB presenting as a classic cutaneous violaceous papule at 66 months following modern hypofractionated 3DCRT for breast cancer, with commentary on radiation technique parameters and their relevance to RAASB risk and clinical presentation. A woman in her late 60s received hypofractionated whole-breast 3DCRT (52.56 Gy: 42.56 Gy/16 fractions plus a 10-Gy boost) for stage IB invasive lobular carcinoma following breast-conserving surgery. An incidental postradiation complex cystic change at the lumpectomy bed was identified at 11 months and monitored with serial imaging and nondiagnostic needle biopsies over 5 years, consistent with benign postradiation fat necrosis unrelated to the subsequent angiosarcoma. At 66 months postradiation, a violaceous cutaneous papule developed on the irradiated skin field. Immediate excisional biopsy established the diagnosis of high-grade RAASB (CD31+ [strong/diffuse], CD34+ [focal/weak], MYC+ [strong/diffuse], Ki-67 70%). Simple mastectomy achieved negative margins (R0 resection); the patient remains disease-free at 6-month follow-up. Conclusion: This case demonstrates that RAASB remains a clinically relevant late complication of breast-conserving therapy even in the era of modern hypofractionated 3DCRT. Recognition of the violaceous cutaneous papule as the hallmark presentation of RAASB should prompt immediate biopsy in any breast cancer survivor with a history of radiotherapy. Prospective studies are needed to characterize RAASB incidence and clinical behavior under modern radiation techniques, as RAASB in the contemporary era may carry a less fulminant course than historically described.
EUVIMED